7 ALS Headlines

1. Herantis’ Potential ALS Treatment, CDNF, Recommended for Orphan Drug Status by EMA

herantis als

Herantis Pharma announced that it has received a positive opinion from the European Medicines Agency’s Committee for Orphan Medicinal Products (COMP) on its application for orphan drug designation for CDNF as a potential treatment for amyotrophic lateral sclerosis (ALS).

A positive opinion is the first step toward orphan drug designation which, in Europe, is issued by the European Commission.

Read more about it: http://bit.ly/1UCyxD2

Leave a Comment

Your email address will not be published. Required fields are marked *